Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 06, 2018 16:01 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals to Present at Upcoming Investor Conferences in November

NEWTON, Mass., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
October 25, 2018 08:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals to Present Data Characterizing Significant Unmet Need in Enteric Hyperoxaluria at ASN Kidney Week 2018

– Highlights Additional Poster Presentation on the Design of URIROX-1, Ongoing Phase 3 Trial Evaluating Reloxaliase in Patients with Enteric Hyperoxaluria – NEWTON, Mass., Oct. 25, 2018 (GLOBE...
October 22, 2018 08:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Presents Preclinical Data Demonstrating Normalized Urine Uric Acid Excretion and Plasma Urate Reduction Following Treatment with ALLN-346

Data Presented in Poster Session at 2018 ACR/ARHP Annual Meeting NEWTON, Mass., Oct. 22, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage biopharmaceutical company...
October 18, 2018 08:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Highlights Ongoing Efforts to Address Rare and Severe Metabolic Disorders Affecting the Kidney with Presentations at Upcoming Medical Meetings

NEWTON, Mass., Oct. 18, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
September 25, 2018 08:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals to Present at Upcoming Investor Conferences in October

NEWTON, Mass., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
August 07, 2018 16:01 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals to Present at 2018 Wedbush PacGrow Healthcare Conference

NEWTON, Mass., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
August 07, 2018 08:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Business Update

- Enrolling Global Phase 3 URIROX-1™ Trial; Plan to Initiate URIROX-2™ in 2H18 - - Treated First Patients in Phase 2 Basket Study of Reloxiliase (ALLN-177) for Primary Hyperoxaluria or Enteric...
July 23, 2018 08:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Announces First Patients Treated in Phase 2 Basket Study of ALLN-177 in Patients with Primary Hyperoxaluria or Enteric Hyperoxaluria and Advanced Chronic Kidney Disease

NEWTON, Mass., July 23, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...
June 19, 2018 08:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Completes Animal Proof-of-Concept Study for ALLN-346, Lead Product Candidate for Hyperuricemia in the Setting of Advanced Chronic Kidney Disease

-- ALLN-346, a Novel, Engineered, Urate Oxidase, Demonstrates Robust Reduction of Plasma and Urine Uric Acid After Oral Administration in an Animal Model of Hyperuricemia -- -- Data Supports...
June 11, 2018 08:00 ET | Source: Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals Appoints Andrew A. F. Hack, M.D., Ph.D., to its Board of Directors

NEWTON, Mass., June 11, 2018 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral...